Biofourmis Inc. scooped up $100 million in a series C round that was led by Softbank Vision Fund 2. The funds are earmarked to accelerate U.S. and global expansion of Biofourmis’ artificial intelligence (AI)-powered health analytics platform and to advance its pipeline of digital therapeutics. The company focuses software-based therapeutics and AI tools for personal predictive care and has U.S. FDA-cleared products that aim to boost clinicians’ ability to remotely monitor and treat patients.
HONG KONG – Singapore is Biofourmis Inc.’s latest destination for its Biovitals Sentinel platform to remotely monitor COVID-19 patients, with the country’s Ministry of Health (MOH) becoming the company’s latest customer.
HONG KONG – Chugai Pharmaceutical Co. Ltd. is hoping to start phase I trials for an as-yet-unnamed digital solution for measuring pain levels in endometriosis patients that it is co-developing with Biofourmis Inc.
Biofourmis Inc. has acquired Los Angeles-based Gaido Health from Takeda Pharmaceuticals in a move designed to significantly expand the company's oncology offerings. Gaido Health's solution will be integrated into Boston-based Biofourmis' Biovitals platform, enhancing its ability to remotely monitor oncology patients at home using a single sensor.
In an effort to gain new insights about the novel coronavirus sweeping the globe, Boston-based Biofourmis Inc. is leveraging its artificial intelligence (AI)-driven remote monitoring platform to monitor Hong Kong patients diagnosed or suspected of having COVID-19. The remote monitoring and disease surveillance program, which kicked off just a few days ago, is being administered by the University of Hong Kong and includes Biofourmis’ Hong Kong-based joint venture, Harmony Medical Inc.
